Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant (NASDAQ: CTSH) has expanded its partnership with Gilead Sciences (NASDAQ: GILD) to enhance value creation through advanced technology applications. The expanded agreement focuses on delivering cost leadership and productivity improvements through AI-driven solutions.
The collaboration will leverage Cognizant's Neuro AI generative AI platform to accelerate value creation, enhance IT and business processes, and improve operational efficiencies across customer service, employee interactions, and business value management. The partnership aims to generate significant cost savings that can be reinvested into Gilead's core life sciences business.
Building on their decade-long relationship supporting Gilead's global IT infrastructure, Cognizant will implement custom-built Gen AI solutions to transform user experience and boost operational efficiency. This expansion enables Gilead to focus on its mission of developing treatments for cancer, HIV, and other diseases while optimizing its technological capabilities.
Cognizant (NASDAQ: CTSH) ha ampliato la sua partnership con Gilead Sciences (NASDAQ: GILD) per incrementare la creazione di valore attraverso applicazioni tecnologiche avanzate. L'accordo ampliato si concentra sulla fornitura di leadership nei costi e miglioramenti della produttività attraverso soluzioni guidate dall'IA.
La collaborazione sfrutterà la piattaforma Neuro AI generativa di Cognizant per accelerare la creazione di valore, migliorare i processi IT e aziendali, e ottimizzare l'efficienza operativa in tutto il servizio clienti, nei rapporti con i dipendenti e nella gestione del valore aziendale. L'obiettivo della partnership è generare significativi risparmi sui costi che possono essere reinvestiti nel core business delle life sciences di Gilead.
Basandosi su oltre dieci anni di relazione a supporto dell'infrastruttura IT globale di Gilead, Cognizant implementerà soluzioni Gen AI su misura per trasformare l'esperienza dell'utente e aumentare l'efficienza operativa. Questa espansione consente a Gilead di concentrarsi sulla sua missione di sviluppare trattamenti per il cancro, l'HIV e altre malattie, ottimizzando al contempo le sue capacità tecnologiche.
Cognizant (NASDAQ: CTSH) ha ampliado su asociación con Gilead Sciences (NASDAQ: GILD) para potenciar la creación de valor a través de aplicaciones tecnológicas avanzadas. El acuerdo ampliado se centra en ofrecer liderazgo en costos y mejoras en la productividad mediante soluciones impulsadas por IA.
La colaboración aprovechará la plataforma Neuro AI generativa de Cognizant para acelerar la creación de valor, mejorar los procesos de TI y comerciales, y optimizar la eficiencia operativa en el servicio al cliente, las interacciones con los empleados y la gestión del valor empresarial. La asociación tiene como objetivo generar ahorros significativos en costos que se pueden reinvertir en el negocio principal de ciencias de la vida de Gilead.
Basándose en su relación de una década respaldando la infraestructura de TI global de Gilead, Cognizant implementará soluciones personalizadas de Gen AI para transformar la experiencia del usuario y aumentar la eficiencia operativa. Esta expansión permite a Gilead enfocarse en su misión de desarrollar tratamientos para el cáncer, el VIH y otras enfermedades, mientras optimiza sus capacidades tecnológicas.
코그니전트 (NASDAQ: CTSH)는 길리어드 사이언스 (NASDAQ: GILD)와의 파트너십을 확대하여 첨단 기술 응용 프로그램을 통해 가치 창출을 강화하고 있습니다. 확대된 계약은 AI 기반 솔루션을 통해 비용 리더십 및 생산성 향상에 중점을 두고 있습니다.
이 협력은 코그니전트의 뉴로 AI 생성 AI 플랫폼을 활용하여 가치 창출을 가속화하고 IT 및 비즈니스 프로세스를 개선하며 고객 서비스, 직원 상호작용 및 비즈니스 가치 관리를 통해 운영 효율성을 높일 것입니다. 파트너십의 목표는 길리어드의 핵심 생명 과학 사업에 재투자할 수 있는 상당한 비용 절감을 창출하는 것입니다.
길리어드의 글로벌 IT 인프라를 지원한 10년 이상의 관계를 바탕으로 코그니전트는 사용자 경험을 변화시키고 운영 효율성을 높이기 위해 맞춤형 생성 AI 솔루션을 구현할 것입니다. 이번 확장은 길리어드가 암, HIV 및 기타 질병 치료 개발이라는 사명에 집중할 수 있도록 하면서 기술적 역량을 최적화할 수 있게 합니다.
Cognizant (NASDAQ: CTSH) a élargi son partenariat avec Gilead Sciences (NASDAQ: GILD) pour améliorer la création de valeur grâce à des applications technologiques avancées. L'accord élargi se concentre sur la fourniture d'un leadership en matière de coûts et d'améliorations de la productivité grâce à des solutions alimentées par l'IA.
La collaboration tirera parti de la plateforme AI générative Neuro de Cognizant pour accélérer la création de valeur, améliorer les processus informatiques et commerciaux, et optimiser l'efficacité opérationnelle dans le service client, les interactions avec les employés et la gestion de la valeur commerciale. L'objectif du partenariat est de générer des économies de coûts significatives qui peuvent être réinvesties dans le cœur de métier des sciences de la vie de Gilead.
S'appuyant sur une relation de plus de dix ans soutenant l'infrastructure informatique mondiale de Gilead, Cognizant mettra en œuvre des solutions Gen AI sur mesure pour transformer l'expérience utilisateur et améliorer l'efficacité opérationnelle. Cette expansion permet à Gilead de se concentrer sur sa mission de développer des traitements contre le cancer, le VIH et d'autres maladies tout en optimisant ses capacités technologiques.
Cognizant (NASDAQ: CTSH) hat seine Partnerschaft mit Gilead Sciences (NASDAQ: GILD) erweitert, um die Wertschöpfung durch fortschrittliche Technologieanwendungen zu verbessern. Der erweiterte Vertrag konzentriert sich auf Kostensenkungen und Produktivitätsverbesserungen durch KI-gesteuerte Lösungen.
Die Zusammenarbeit wird die Neuro AI Generative AI-Plattform von Cognizant nutzen, um die Wertschöpfung zu beschleunigen, IT- und Geschäftsprozesse zu verbessern und die Betriebseffizienz in den Bereichen Kundenservice, Mitarbeiterinteraktionen und Wertmanagement zu steigern. Ziel der Partnerschaft ist es, erhebliche Kosteneinsparungen zu erzielen, die in das Kerngeschäft der Lebenswissenschaften von Gilead reinvestiert werden können.
Aufbauend auf ihrer jahrzehntelangen Beziehung zur Unterstützung der globalen IT-Infrastruktur von Gilead wird Cognizant maßgeschneiderte Gen AI-Lösungen implementieren, um das Benutzererlebnis zu verbessern und die Betriebseffizienz zu steigern. Diese Erweiterung ermöglicht es Gilead, sich auf seine Mission zu konzentrieren, Behandlungen für Krebs, HIV und andere Krankheiten zu entwickeln, und gleichzeitig seine technologischen Fähigkeiten zu optimieren.
- Expansion of existing partnership indicates strong business relationship and trust
- Implementation of AI solutions expected to generate significant cost savings
- Enhanced operational efficiencies through advanced technology applications
- Long-term strategic partnership securing steady revenue stream
- None.
Insights
This strategic partnership expansion marks a significant evolution in Cognizant's business model, positioning the company at the forefront of AI-driven digital transformation in the healthcare sector. The deal showcases three critical elements that strengthen Cognizant's market position:
1. Revenue Stream Enhancement
The expanded agreement with a major pharmaceutical company like Gilead represents a high-value, long-term engagement that provides stable recurring revenue. Such partnerships typically generate higher margins compared to traditional IT services due to the specialized nature of healthcare technology solutions.
2. AI Capability Showcase
The implementation of Cognizant's Neuro AI platform serves as a powerful proof-of-concept for the company's AI capabilities, potentially attracting similar large-scale partnerships in the life sciences sector. This positions Cognizant advantageously in the highly competitive market for AI-driven enterprise solutions.
3. Strategic Market Positioning
The partnership reinforces Cognizant's expertise in the healthcare/life sciences vertical, a sector experiencing rapid digital transformation with significant budget allocation for technology modernization. The focus on cost optimization and efficiency improvements through AI applications demonstrates Cognizant's ability to deliver tangible business value in complex regulated environments.
The emphasis on cost leadership and productivity enhancement suggests potential margin improvements for Cognizant, as such implementations typically involve higher-value services compared to traditional IT support. The company's ability to leverage existing infrastructure while introducing advanced AI capabilities indicates an efficient scaling strategy that could drive improved profitability.
This partnership represents a significant advancement in the application of AI within pharmaceutical operations, with several key implications for the industry:
Operational Innovation
The integration of generative AI across Gilead's operations, particularly in customer service and employee interactions, signals a shift toward more automated and efficient pharmaceutical operations. This could set new industry standards for operational efficiency in big pharma.
Cost Optimization Strategy
The focus on cost leadership through AI implementation indicates a broader industry trend where pharmaceutical companies are leveraging technology to redirect resources toward core research and development activities. This approach could become a blueprint for other pharmaceutical companies seeking to optimize their operations while maintaining research excellence.
Digital Infrastructure Evolution
The comprehensive nature of this AI implementation, covering multiple use cases and business processes, suggests a fundamental transformation in how pharmaceutical companies approach their digital infrastructure. This could accelerate the adoption of AI-driven solutions across the pharmaceutical industry, particularly in areas like clinical trial management and drug discovery support systems.
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value
Over the last decade, Cognizant has helped support Gilead's global IT infrastructure, platforms, applications and advanced analytics, and leads initiatives designed to accelerate its digital transformation. Today's announcement builds on a collaboration aimed at creating capacity to allow Gilead to continue its focus and mission, aimed at discovering and delivering critical medicines for cancer, HIV and other diseases.
"Cognizant continues to provide critical expertise as we advance our technology journey," said Joydeep Ganguly, SVP & Head – Corporate Operations and Interim CIO at Gilead. "The expansion of this partnership is pivotal in accelerating our capabilities roadmap while driving a new level of cost leadership across our technology programs. This collaboration aims to bring innovative changes to Gilead's business, exploring new possibilities and enhancing our operations in novel ways."
Expanding on the company's partnership, Cognizant intends to leverage its Neuro AI generative AI platform to assist Gilead in accelerating value creation, enhancing IT and business processes, and improving operational efficiencies. This initiative aims to provide significant cost savings, which can be reinvested into Gilead's core life sciences business. As part of this expanded agreement, Cognizant also intends to transform the user experience of IT services with custom-built Gen AI solutions that allow Gilead to benefit from greater efficiency and user experience.
"We're proud of our longstanding relationship with Gilead, a leader in leveraging advanced technologies, and are excited about expanding our partnership in a new dimension with the company to deliver transformative treatments globally," said Surya Gummadi, EVP and President, Cognizant Americas. "Our teams will work together to transform user engagement, and boost productivity and cost savings for Gilead to focus on the critical work they do around preventing and treating life-threatening illnesses."
"This agreement allows us to provide end-to-end Cognizant capabilities through our life sciences domain expertise to provide value acceleration to Gilead," said Mohammad Haque, SVP, Global Large Deals Lead and Business Unit Head, Life Sciences, Cognizant. "Utilizing Cognizant's premier managed services frameworks and tools we intend to enhance operational efficiencies with leading-edge automation."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
About Gilead
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information, contact:
Natalie Steffen
Natalie.Steffen@cognizant.com
300 Frank W. Burr Blvd. Suite 36, 6th Floor
+1 201 801 0233 Cognizant.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cognizant-and-gilead-expand-partnership-to-drive-greater-value-through-advanced-technology-applications-302363834.html
SOURCE Cognizant Technology Solutions Corporation
FAQ
What are the key benefits of Cognizant's expanded partnership with Gilead Sciences?
How will Cognizant's Neuro AI platform benefit Gilead Sciences?
What areas will CTSH's AI solutions target in the Gilead partnership?
How long has Cognizant been supporting Gilead's IT infrastructure?
What will Gilead do with the cost savings from CTSH's technology solutions?
